Uptravi (Selexipag)

Save 70% on Brand Name Uptravi or over 95% with generic version of Uptravi today.

For more info on generic medicines made by Cipla generic medicine click here

Brand name Uptravi comes in Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer for all Uptravi from Europe: Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse Belgium

Information about Uptravi (Selexipag)

Uptravi is a medication containing the active ingredient selexipag, which is used to treat pulmonary arterial hypertension (PAH). PAH is a rare and serious condition where high blood pressure occurs in the arteries of the lungs, making it harder for the heart to pump blood through the lungs. Selexipag helps by relaxing and dilating the blood vessels in the lungs, lowering blood pressure and improving symptoms.

Product Highlights

• Uptravi is primarily prescribed to treat PAH, a condition that causes elevated blood pressure in the pulmonary arteries and leads to shortness of breath, fatigue, and reduced exercise capacity.
• Selexipag can help improve the ability to perform physical activities in individuals with PAH.

Key Ingredient

• Selexipag

Key Benefits

• Selexipag helps reduce the high blood pressure in the pulmonary arteries, which can improve symptoms like shortness of breath and fatigue.
• By reducing pulmonary pressure, Uptravi can improve the ability to perform physical activities, enhancing overall quality of life.
• It can be used over a long period as part of a treatment plan for PAH, and can be used in combination with other PAH therapies.

Direction of Use

• Uptravi is typically started at a low dose, which is gradually increased over time to minimize side effects. The usual starting dose is 200 mcg twice a day, with adjustments based on the patient's tolerance.
• It can be taken with or without food.
• The tablets should be taken whole and not chewed, crushed, or broken. 
• Consistent use of Uptravi is important for managing PAH effectively. Missing doses can affect the efficacy of the treatment.

Safety Concerns

• Common side effects of Uptravi include headaches, diarrhea, nausea, jaw pain, and flushing. These side effects are usually temporary and tend to get better with time. 
• Selexipag may affect liver function, so liver function tests are recommended before starting treatment and during therapy.
• As Uptravi affects blood pressure, there may be concerns about low blood pressure (hypotension) or other cardiovascular effects. Patients should be monitored for changes in blood pressure and heart rate.
• Since prostacyclin pathways can influence platelet aggregation, Uptravi may increase the risk of bleeding. Patients with a history of bleeding disorders should use caution. 
• Selexipag is not recommended during pregnancy, as its effects on the fetus are unknown. Women of childbearing age should use reliable contraception during treatment with this medication. 

Avoid Uptravi (Selexipag) If

• If you have a known hypersensitivity to selexipag or any of the ingredients in Uptravi, it should be avoided.
• Uptravi is contraindicated in patients with severe liver dysfunction, as it may worsen liver function.
• The medication should not be used during pregnancy unless clearly necessary, and it is contraindicated during breastfeeding.
• Caution is required if you have severe heart problems or low blood pressure, as the drug may exacerbate these conditions.